Overview
APRE market data
Price History
APRE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.93 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.24 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.55 – $2.22 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $8.2 · P/B 0.45 · P/S 28.60.
Company news
Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid TumorsBenzinga · Jun 1, 2026, 12:08 PM
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6Benzinga · May 14, 2026, 1:17 PM
Earnings Scheduled For May 13, 2026Benzinga · May 13, 2026, 11:11 AM
Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) EstimateBenzinga · May 13, 2026, 10:36 AM
8-K filing — Aprea Therapeutics, Inc. (APRE)SEC EDGAR · May 13, 2026, 10:35 AM